Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + bevacizumab + paclitaxel + cisplatin
- Development stage
- Phase 2
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Toripalimab (JS001) is a humanized IgG4 monoclonal antibody directed against the programmed cell death protein 1 (PD-1) receptor. It functions as an immune checkpoint inhibitor by blocking the interaction between PD-1 and its ligands (PD-L1 and PD-L2), thereby restoring T-cell mediated anti-tumor immunity. In a Phase II clinical trial (NCT04973904) conducted at Peking Union Medical College Hospital, toripalimab is being evaluated in combination with bevacizumab (an anti-VEGF monoclonal antibody) and chemotherapy (paclitaxel and cisplatin or carboplatin) for the first-line treatment of patients with recurrent, refractory, or metastatic cervical cancer. This multi-component regimen combines immunotherapy, anti-angiogenesis, and cytotoxic chemotherapy to improve objective response rates and survival outcomes in advanced cervical cancer patients.
- Brand names
- Tuoyi
- Other names
- Toripalimab + Bevacizumab + Paclitaxel + CisplatinToripalimab + Chemo + Bevacizumab
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on toripalimab + bevacizumab + paclitaxel + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + bevacizumab + paclitaxel + cisplatin.